{"disease":{"id":"rash-due-to-epidermal-growth-factor-receptor-inhibitors","name":"rash due to epidermal growth factor receptor inhibitors"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07469488","title":"A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":122,"lead_sponsor_name":"Shanghai Pulmonary Hospital, Shanghai, China","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}